TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07832292: A Phase 2, Open-label, Multicenter, Single-arm Trial of JNJ-101556143, an Androgen Receptor-targeted Regulated Induced Proximity Targeting Chimera (RIPTAC™) Therapeutic in Participants With Metastatic Androgen Pathway Mo

Sponsor: Janssen Research & Development, LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$11,873,400

Rescue Site Savings

+$7,854,000

Unlock Full NCT07832292 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07832292 Rescue Dossier →